{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:55:01Z","timestamp":1792018501201,"version":"4.4.0"},"reference-count":24,"publisher":"Wiley","issue":"s447","license":[{"start":{"date-parts":[[2007,1,2]],"date-time":"2007-01-02T00:00:00Z","timestamp":1167696000000},"content-version":"vor","delay-in-days":672,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Paediatrica"],"published-print":{"date-parts":[[2005,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The treatment of disordered lipoprotein metabolism with the statin class of drugs is one of the most striking successes in the field of applied medical science: here the use of selective inhibitors of the first committed step of cholesterol biosynthesis, in a complex and highly regulated pathway, leads to improved outcome from a common lipid storage disease that is a blight on whole populations \u2013 atherosclerosis. By the same token, substrate reduction is an emerging therapeutic strategy for the arcane field of the lysosomal storage diseases (LSDs). Reduced biosynthesis of glucosylceramide is postulated to allow correction of the imbalance between formation and breakdown of glycosphingolipids; the therapeutic effect of substrate reduction depends upon the presence of residual hydrolytic activity towards those accumulated glycosphingolipid substrates derived from glucosylceramide. First pioneered in the laboratory by Norman Radin, this approach has now been introduced into the clinic: based on the ability to inhibit uridine diphosphate glucosylceramide transferase, the semi\u2010selective iminosugar,\n                    <jats:italic>N<\/jats:italic>\n                    \u2010butyldeoxynojirimycin, is licensed for the treatment of type 1 Gaucher disease.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Inhibition of substrate formation has wide application in the treatment of LSDs. Decreased glucosylceramide biosynthesis has therapeutic potential in glycosphingolipidoses other than Gaucher disease, and offers promise in several neurodegenerative storage disorders that are currently beyond the reach of other procedures. The results of ongoing clinical trials of miglustat in type 3 Gaucher disease, Niemann\u2013Pick disease type C and GM2 gangliosidosis are eagerly awaited.\n                  <\/jats:p>","DOI":"10.1111\/j.1651-2227.2005.tb02116.x","type":"journal-article","created":{"date-parts":[[2010,8,6]],"date-time":"2010-08-06T23:48:52Z","timestamp":1281138532000},"page":"69-75","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Substrate reduction therapy for lysosomal storage diseases"],"prefix":"10.1111","volume":"94","author":[{"given":"T M","family":"Cox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,1,2]]},"reference":[{"key":"e_1_2_12_2_2","doi-asserted-by":"publisher","DOI":"10.1159\/000112332"},{"key":"e_1_2_12_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-3084(80)90057-2"},{"key":"e_1_2_12_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2275(20)38673-9"},{"key":"e_1_2_12_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)37202-2"},{"key":"e_1_2_12_6_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.276.5311.428"},{"key":"e_1_2_12_7_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.11.6388"},{"key":"e_1_2_12_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(99)00384-6"},{"key":"e_1_2_12_9_2","first-page":"472","article-title":"Miglustat. Oxford GlycoSciences\/Actelion","volume":"4","author":"Lachmann RH","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_12_10_2","first-page":"5","article-title":"Small molecule inhibitors of glucosylceramide synthase for the treatment of Gaucher disease","volume":"10","author":"Shayman JA","year":"2002","journal-title":"Clinical Perspectives on Lysosomal Storage Disorders"},{"key":"e_1_2_12_11_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389200013338414"},{"key":"e_1_2_12_12_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-72-8-1919"},{"key":"e_1_2_12_13_2","first-page":"139","article-title":"The safety and efficacy of combination N\u2010butyl\u2010deoxynojirimycin (SC\u201048334) and zidovudine in patients with HIV\u20101 infection and 200\u2013500 CD4 cells\/mm3","volume":"7","author":"Fischl MA","year":"1994","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_12_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199510050-00008"},{"key":"e_1_2_12_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02161-9"},{"key":"e_1_2_12_16_2","doi-asserted-by":"publisher","DOI":"10.1006\/bcmd.2002.0497"},{"key":"e_1_2_12_17_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:BOLI.0000045756.54006.17"},{"key":"e_1_2_12_18_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1025902113005"},{"key":"e_1_2_12_19_2","doi-asserted-by":"publisher","DOI":"10.1042\/bst0270409"},{"key":"e_1_2_12_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2004.04.011"},{"key":"e_1_2_12_21_2","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2003.1276"},{"key":"e_1_2_12_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)10034-X"},{"key":"e_1_2_12_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(01)00396-7"},{"key":"e_1_2_12_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2004.05.002"},{"key":"e_1_2_12_25_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M311591200"}],"container-title":["Acta Paediatrica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1651-2227.2005.tb02116.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1651-2227.2005.tb02116.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T10:05:24Z","timestamp":1695809124000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1651-2227.2005.tb02116.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":24,"journal-issue":{"issue":"s447","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["10.1111\/j.1651-2227.2005.tb02116.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1651-2227.2005.tb02116.x","archive":["Portico"],"relation":{},"ISSN":["0803-5253","1651-2227"],"issn-type":[{"value":"0803-5253","type":"print"},{"value":"1651-2227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3]]},"assertion":[{"value":"2007-01-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}